Format

Send to

Choose Destination
Annu Rev Pharmacol Toxicol. 2019 Oct 3. doi: 10.1146/annurev-pharmtox-010818-021441. [Epub ahead of print]

Beyond THC and Endocannabinoids.

Author information

1
Laboratory of Cardiovascular Physiology and Tissue Injury and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20852, USA; email: ppacher@gmail.com.
2
Institute for Drug Research, Faculty of Medicine, Hebrew University, Jerusalem 9112102, Israel; email: raphaelm@ekmd.huji.ac.il.

Abstract

Research in the cannabinoid field, namely on phytocannabinoids, the endogenous cannabinoids anandamide and 2-arachidonoyl glycerol and their metabolizing and synthetic enzymes, the cannabinoid receptors, and anandamide-like cannabinoid compounds, has expanded tremendously over the last few years. Numerous endocannabinoid-like compounds have been discovered. The Cannabis plant constituent cannabidiol (CBD) was found to exert beneficial effects in many preclinical disease models ranging from epilepsy, cardiovascular disease, inflammation, and autoimmunity to neurodegenerative and kidney diseases and cancer. CBD was recently approved in the United States for the treatment of rare forms of childhood epilepsy. This has triggered the development of many CBD-based products for human use, often with overstated claims regarding their therapeutic effects. In this article, the recently published research on the chemistry and biological effects of plant cannabinoids (specifically CBD), endocannabinoids, certain long-chain fatty acid amides, and the variety of relevant receptors is critically reviewed. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 60 is January 6, 2020. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center